Evogene (EVGN) Expected to Release Quarterly Earnings on Tuesday

Evogene (NASDAQ:EVGN) will likely be issuing its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Evogene to announce earnings of ($0.27) per share and revenue of $0.3250 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:00 AM ET.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.35 million.

Evogene Stock Up 5.4%

Shares of NASDAQ:EVGN opened at $0.63 on Tuesday. Evogene has a 52-week low of $0.37 and a 52-week high of $1.50. The stock has a market cap of $5.51 million, a price-to-earnings ratio of -0.45 and a beta of 1.40. The business has a 50-day moving average price of $0.53 and a 200-day moving average price of $0.73.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Evogene has an average rating of “Sell”.

Hedge Funds Weigh In On Evogene

A number of large investors have recently bought and sold shares of EVGN. XTX Topco Ltd purchased a new position in shares of Evogene during the 4th quarter valued at approximately $25,000. Jane Street Group LLC raised its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,387 shares during the period. Finally, Citadel Advisors LLC raised its position in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares during the period. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.